GSE183535 MYC inhibition HeLa 0 v 6 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE183535_MYC inhibition_HeLa_0_v_6_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE183535_MYC inhibition_HeLa_0_v_6_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE183535_MYC inhibition_HeLa_0_v_6_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE183535_MYC inhibition_HeLa_0_v_6_human_up.

Results found

Linked to

 

Label

Description

 

Gene

A-kinase anchoring protein 17A

Gene

long intergenic non-protein coding RNA 3040

Gene

urothelial cancer associated 1

Gene

Myb/SANT DNA binding domain containing 7

Gene

long intergenic non-protein coding RNA 1128

Gene

ring finger protein 216 pseudogene 1

Gene

chromosome 6 open reading frame 47

Gene

PHLDA1 antisense RNA 1

Gene

FLNB antisense RNA 1

Gene

myosin XVB

  • Gene

    A-kinase anchoring protein 17A


  • Gene

    long intergenic non-protein coding RNA 3040


  • Gene

    urothelial cancer associated 1


  • Gene

    Myb/SANT DNA binding domain containing 7


  • Gene

    long intergenic non-protein coding RNA 1128


  • Gene

    ring finger protein 216 pseudogene 1


  • Gene

    chromosome 6 open reading frame 47


  • Gene

    PHLDA1 antisense RNA 1


  • Gene

    FLNB antisense RNA 1


  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.